

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: RFA2/22 - Risk Factors for Atherosclerosis

Deadline: 14.10.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(111) Cholesterol					306							306	295	96%
— Samples and groups	[mmol/L]													
Sample A		7,00	0,23	3,3	306	CVP	7 0,033	8%	6,44	7,56		306	298	97%
(1) Enzyme method CHOD-PAP		7,00	0,23	3,3	306	0						306		
Sample B		3,35	0,11	3,4	306	CVP	3,35 0,016	8%	3,08	3,62		306	301	98%
(1) Enzyme method CHOD-PAP		3,35	0,11	3,4	306	0						306		
(112) Triacylglycerols					306							306	303	99%
— Samples and groups	[mmol/L]													
Sample A		2,16	0,069	3,2	306	CVP	2,16 ,0096	15%	1,83	2,49		306	305	100%
(1) Photometric enzyme (GPO-PAP)		2,16	0,069	3,2	292	0						292		
(2) Enzymatic UV method		2,12	0,065	3,1	14	0						14		
Sample B		1,04	0,044	4,3	306	CVP	1,04 ,0062	15%	0,884	1,2		306	303	99%
(1) Photometric enzyme (GPO-PAP)		1,04	0,044	4,3	292	0						292		
(2) Enzymatic UV method		1,03	0,044	4,2	14	0						14		
(113) Cholesterol HDL					310							310	304	98%
— Samples and groups	[mmol/L]													
Sample A		1,89	0,09	4,8	310	CVP	1,89 0,013	15%	1,6	2,18		310	310	100%
(2) Direct determination		1,89	0,09	4,7	307	0						307		
Other					3	0						3		
Sample B		0,920	0,048	5,3	310	CVP	0,92 ,0067	15%	0,782	1,06		310	304	98%
(2) Direct determination		0,920	0,048	5,2	307	0						307		
Other					3	0						3		
(114) Apolipoprotein AI					87							87	86	99%
— Samples and groups	[g/L]													
Sample A		2,14	0,16	7,3	87	CVP	2,14 0,041	21%	1,69	2,59		87	86	99%
(2) Immunoturbidimetry		2,15	0,15	7,2	77	0						77		
(3) Immunonephelometry		2,12	0,11	5,3	9	0						9		
Other					1	0						1		
Sample B		1,04	0,07	6,7	87	CVP	1,04 0,018	21%	0,821	1,26		87	87	100%
(2) Immunoturbidimetry		1,03	0,07	6,8	77	0						77		
(3) Immunonephelometry		1,06	0,015	1,4	9	0						9		
Other					1	0						1		
(115) Apolipoprotein B					102							102	99	97%
— Samples and groups	[g/L]													
Sample A		1,31	0,067	5,1	102	CVP	1,31 0,016	18%	1,07	1,55		102	100	98%
(2) Immunoturbidimetry		1,31	0,064	4,9	93	0						93		
(3) Immunonephelometry		1,37	0,16	11	8	0						8		
Other					1	0						1		
Sample B		0,642	0,035	5,5	102	CVP	0,642 ,0085	18%	0,526	0,758		102	100	98%
(2) Immunoturbidimetry		0,642	0,035	5,4	93	0						93		
(3) Immunonephelometry		0,639	0,043	6,7	8	0						8		
Other					1	0						1		
(116) Cholesterol LDL (calculation)					122							122	116	95%
— Samples and groups	[mmol/L]													
Sample A		4,15	0,22	5,3	122	CVP	4,15 0,049	15%	3,52	4,78		122	119	98%
(0) Not specified		4,15	0,22	5,3	122	0						122		
Sample B		1,97	0,13	6,5	122	CVP	1,97 0,029	15%	1,67	2,27		122	118	97%
(0) Not specified		1,97	0,13	6,5	122	0						122		
(118) Cholesterol LDL (direct determ.)					237							237	221	93%
— Samples and groups	[mmol/L]													
Sample A		4,27	0,45	11	237	CVP	4,27 0,072	15%	3,62	4,92		237	223	94%
(1) Removed non-LDL (peroxidase)		4,27	0,49	11	73	0						73		
(2) Removed non-LDL (catalase and perox.)		4,45	0,37	8,3	85	0						85		
(3) Selective determination		4,06	0,39	9,5	72	0						72		
(99) Another measurement principle		4,21	0,45	11	7	0						7		
Sample B		2,04	0,17	8,3	237	CVP	2,04 0,027	15%	1,73	2,35		237	230	97%
(1) Removed non-LDL (peroxidase)		2,04	0,19	9,2	73	0						73		

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: RFA2/22 - Risk Factors for Atherosclerosis

Deadline: 14.10.2022

Test	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel}
							AV	U _{AV}	D _{max}	LL	UL				
(118) Cholesterol LDL (direct determ.)	[mmol/L]				237								237	221	93%
--- Samples and groups ---															
Sample B		2,04	0,17	8,3	237		CVP	2,04	0,027	15%	1,73	2,35	237	230	97%
(2) Removed non-LDL (catalase and perox.)		2,10	0,13	6,3	85	0							85		
(3) Selective determination		1,97	0,16	8,0	72	0							72		
(99) Another measurement principle		2,01	0,17	8,5	7	0							7		
(117) Lipoprotein (a) [g/L]	[g/L]				34								34	30	88%
--- Samples and groups ---															
Sample A		0,322	0,025	7,8	34		CVP	0,322	0,011	32%	0,218	0,426	34	31	91%
(2) Immunoturbidimetry		0,325	0,018	5,7	28	0							28		
(3) Immunonephelometry		0,280	0,10	37	6	0							6		
Sample B		0,181	0,017	9,5	34		CVP	0,181	,0072	32%	0,123	0,239	34	30	88%
(2) Immunoturbidimetry		0,182	0,012	6,7	28	0							28		
(3) Immunonephelometry		0,161	0,058	36	6	0							6		
(119) Lipoprotein (a) [nmol/L]	[nmol/L]				36								36	33	92%
--- Samples and groups ---															
Sample A		63,4	4,2	6,6	36		CVP	63,4	1,7	20%	50,7	76,1	36	34	94%
(2) Immunoturbidimetry		63,4	4,2	6,6	36	0							36		
Sample B		32,1	2,9	9,1	36		CVP	32,1	1,2	20%	25,6	38,6	36	33	92%
(2) Immunoturbidimetry		32,1	2,9	9,1	36	0							36		

st_kn_p

End of report

Printed: 23.10.2022